{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:29:08Z","timestamp":1785446948383,"version":"3.56.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>The aim of this mini-review is to discuss the main antiplatelet agents that have been successfully used in the secondary prevention of non-cardioembolic ischemic stroke and transient ischemic attacks (TIA). The methodology is based on a literature review of available peer-reviewed English studies listed in PubMed. The findings reveal that aspirin remains a reliable antiplatelet agent in the secondary prevention of acute non-cardioembolic ischemic stroke and TIA. Nevertheless, currently, there are also other agents, i.e., ticagrelor, clopidogrel, and cilostazol, that can be applied. In addition, the results indicate that time is significant not only in severe stroke but also in non-severe stroke and TIA, which suggests that antiplatelet therapy should be applied within 24 h after the first symptoms because early treatment can lead to an improvement in neurological outcomes and reduce the chance of an early subsequent stroke.<\/jats:p>","DOI":"10.3389\/fneur.2021.626106","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T07:04:09Z","timestamp":1614236649000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Martin","family":"Vali\u0161","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"Kl\u00edmov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Novotn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Herzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12883-020-01808-y","article-title":"Dual versus mono antiplatelet therapy for acute non-cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis","volume":"20","author":"Albay","year":"2020","journal-title":"BMC Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1016\/j.lpm.2016.10.003","article-title":"Epidemiology of stroke in Europe and trends for the 21st century","volume":"45","author":"B\u00e9jot","year":"2016","journal-title":"Presse Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1161\/STROKEAHA.120.029606","article-title":"Burden of stroke in Europe. Thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years","volume":"51","author":"Wafa","year":"2020","journal-title":"Stroke"},{"key":"B4","unstructured":"Types of Strokes and Stroke Risks2020"},{"key":"B5","unstructured":"2020"},{"key":"B6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1503\/cmaj.140355","article-title":"Diagnosis and management of acute ischemic stroke: speed is critical","volume":"187","author":"Musuka","year":"2015","journal-title":"CMAJ."},{"key":"B7","doi-asserted-by":"publisher","first-page":"P301","DOI":"10.1016\/S1474-4422(17)30038-8","article-title":"Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial","volume":"16","author":"Amarenco","year":"2017","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S.0140-6736(03)14544-8","article-title":"Stroke","volume":"362","author":"Warlow","year":"2003","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/STROKEAHA.118.023954","article-title":"Antiplatelet therapy in ischemic stroke and transient ischemic attack","volume":"50","author":"Hackam","year":"2019","journal-title":"Stroke."},{"key":"B10","unstructured":"PaceWD\n            EarlA\n            BryantC\n            HansenC\n          Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke2020"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 Guidelines for the early management of acute ischemic stroke: a Guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2169\/internalmedicine.56.7760","article-title":"Dual therapy with aspirin and cilostazol may improve platelet aggregation in noncardioembolic stroke patients: a pilot study","volume":"56","author":"Ohnuki","year":"2017","journal-title":"Intern Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1574884712666170227154654","article-title":"Potential usefulness of clopidogrel pharmacogenetics in cerebral endovascular procedures and carotid artery stenting","volume":"12","author":"Duconge","year":"2017","journal-title":"Curr Clin Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","article-title":"Net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease","volume":"142","author":"Steffel","year":"2020","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3988\/jcn.2014.10.3.189","article-title":"Dual antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack: pros and cons","volume":"10","author":"Hong","year":"2014","journal-title":"J Clin Neurol"},{"key":"B18","first-page":"640","article-title":"Dual antiplatelet therapy for secondary stroke prevention: use of clopidogrel and acetylsalicylic acid after noncardioembolic ischemic stroke","volume":"62","author":"Koziol","year":"2016","journal-title":"Can Fam Physician"},{"key":"B19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5507\/bp.2010.031","article-title":"Oral antiplatelet therapy in stroke prevention","volume":"154","author":"Kral","year":"2010","journal-title":"Minireview Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"B20","unstructured":"2020"},{"key":"B21","unstructured":"ATC\/DDD Index2020"},{"key":"B22","first-page":"852","article-title":"The changes in mean platelet volume after using of antiplatelet drugs in acute ischemic stroke: a randomized controlled trial","volume":"8","author":"Haungsaithong","year":"2015","journal-title":"J Med Assoc Thai"},{"key":"B23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jamaneurol.2018.0247","article-title":"Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial","volume":"75","author":"Jing","year":"2018","journal-title":"JAMA Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jocn.2014.05.038","article-title":"Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke","volume":"22","author":"He","year":"2015","journal-title":"J Clin Neurosci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e012652","DOI":"10.1161\/JAHA.119.012652","article-title":"Acute aspirin plus cilostazol dual therapy for noncardioembolic stroke patients within 48 hours of symptom onset","volume":"8","author":"Aoki","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1001\/jamaneurol.2020.4396","article-title":"Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of disabling stroke: a randomized clinical trial","volume":"7","author":"Amarenco","year":"2020","journal-title":"JAMA Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischemic stroke in Japan: a multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lancet Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22480","article-title":"Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischemic stroke or transient ischemic attack: the TARDIS RCT","volume":"22","author":"Bath","year":"2018","journal-title":"Health Technol Assess"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1607181","DOI":"10.1155\/2019\/1607181","article-title":"Benefits and risks of clopidogrel vs. aspirin monotherapy after recent ischemic stroke: a systematic review and meta-analysis","volume":"2019","author":"Paciaroni","year":"2019","journal-title":"Cardiovasc Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1161\/STROKEAHA.118.023978","article-title":"Optimal duration of aspirin plus clopidogrel after ischemic stroke or transient ischemic attack. A systematic review and meta-analysis","volume":"50","author":"Rahman","year":"2019","journal-title":"Stroke."},{"key":"B31","unstructured":"Vela-DuarteD\n          31424481Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA2018"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1161\/STROKEAHA.118.024497","article-title":"Antiplatelet therapy after noncardioembolic stroke: an individual patient data network meta-analysis","volume":"50","author":"Greving","year":"2019","journal-title":"Stroke."},{"key":"B33","doi-asserted-by":"publisher","first-page":"k5108","DOI":"10.1136\/bmj.k5108","article-title":"Clopidogrel plus aspirin versus aspirin alone for acute minor ischemic stroke or high risk transient ischemic attack: systematic review and meta-analysis","volume":"363","author":"Hao","year":"2018","journal-title":"BMJ"},{"key":"B34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/14656566.2019.1707181","article-title":"The use of cilostazol for secondary stroke prevention: isn't it time it's evaluated in Western countries?","volume":"21","author":"Di Napoli","year":"2020","journal-title":"Expert Opin Pharmacother."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.626106\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T07:04:39Z","timestamp":1614236679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.626106\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":34,"alternative-id":["10.3389\/fneur.2021.626106"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.626106","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"article-number":"626106"}}